Miragen Therapeutics, Inc. (MGEN) Stock: Is This Biotech Stock Worth Your Time?


Miragen Therapeutics, Inc. (MGEN) is making a move down in the market today. The company, one that is focused in the biotech industry, is presently trading at $1.30 after a move down of -17.20% so far in today’s session. As it relates to biotechnology stocks, there are quite a few aspects that have the ability to lead to movement in the market. News is one of the most common reasons for movement. Here are the most recent trending headlines surrounding MGEN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-07-19 08:45PM Signal Genetics, Inc. (MGEN) Reports Q2 Loss, Tops Revenue Estimates
04:05PM miRagen Reports Second Quarter 2019 Results; Regains Global Rights to MRG-110 and Announces Corporate Restructuring
Jul-31-19 10:36AM Analysts Estimate Signal Genetics, Inc. (MGEN) to Report a Decline in Earnings: What to Look Out for
Jul-24-19 08:00AM Miragen Therapeutics to Report Second Quarter 2019 Financial Results and Host a Conference Call on August 7th
Jun-21-19 01:45PM Some Miragen Therapeutics (NASDAQ:MGEN) Shareholders Have Copped A Big 66% Share Price Drop

However, any time investors are making an investing decision, prospective investors should look into much more than just news, this is especially the case in the speculative biotechnology sector. Here’s what’s happening with Miragen Therapeutics, Inc..

Recent Trends From MGEN

While a move toward the top in a single session, like the fall that we’re seeing from Miragen Therapeutics, Inc. might make some investors fearful, a single session decline alone shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It is generally smart to look at trends further out than a single session. When it comes to MGEN, below are the movements that investors have seen:

  • Past Seven Days – Over the last week, MGEN has generated a change in price in the amount of -36.27%.
  • Past 30 Days – The monthly performance from Miragen Therapeutics, Inc. comes to -38.97%.
  • Past 3 Months – Over the last 3 months, the company has generated a return on investment that comes to -53.74%
  • Past Six Months – In the previous six months, we’ve seen a performance that amounts to -56.23% from the company.
  • Year To Date – Since the the last trading session of last year MGEN has produced a return of -57.10%.
  • Annually – Lastly, over the past full year, investors have seen performance of -79.33% from MGEN. Throughout this period, the stock has traded at a high of -79.78% and a low price of 1.34%.

Ratios To Pay Attention To

Digging into various key ratios associated with a stock can provide prospective investors a view of just how risky and/or rewarding a stock pick might be. Here are a few of the key ratios to look at when digging into MGEN.

Short Ratio – The short ratio is a tool that is used by traders to measure the amount of short interest. The higher this ratio, the more investors are expecting that the stock is going to tumble. Throughout the sector, biotechnology stocks tend to have a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the space. Nonetheless, with regard to Miragen Therapeutics, Inc., the stock’s short ratio amounts to 2.23.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Basically, they measure If a company is able to cover its debts when they come due with only quick assets or current assets. In the biotechnology sector, companies are reliant on the continuation of investor support, the current and quick ratios can seem bad. However, several gems in the biotech space come with good quick and current ratios. As it relates to MGEN, the quick and current ratios add up to 7.90 and 7.90 respectively.  

Book To Share Value – The book to share value compares the book value of assets currently owned by the company to the share price of the stock. In this particular case, the book to share value ratio is 1.33.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the value of the company’s stock. Several clinical stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotech sector, this is an important ratio to think about. As it relates to MGEN, the cash to share value works out to 1.59.

What Analysts Think About Miragen Therapeutics, Inc.

While it’s rarely a smart idea to unknowingly follow the opinions of analysts, it is a good idea to consider their thoughts in order to validate your own due diligence before making an investment decision in the biotechnology sector. Here are the recent moves that we have seen from analysts as it relates to MGEN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jan-04-19 Initiated Robert W. Baird Outperform
Dec-31-18 Resumed B. Riley FBR Buy $18.50
Mar-29-18 Initiated Jefferies Buy $14
Mar-09-18 Initiated Evercore ISI Outperform $19
Jan-05-18 Initiated B. Riley FBR, Inc. Buy $15.50

Is Big Money Interested in Miragen Therapeutics, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in MGEN, here’s what we’re seeing:

  • Institutional Investors – Currently, institutions hold 45.20% of the company. However, it is important to mention that the ownership held by institutions has seen a move in the amount of 0.03% throughout the last 3 months.
  • Insider Moves – As far as insiders go, insiders of the company currently hold 10.65% of Miragen Therapeutics, Inc.. Their ownership of the company has moved 0.00% over the last quarter.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 32.03M shares of Miragen Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, MGEN has a float of 27.90M.

It’s also important to follow the short float. Think about it, if a large percentage of the float available for trading is sold short, the overall opinion in the market is that the stock is going to fall. As far as it relates to MGEN, the percentage of the float that is shorted is 1.42%. In general, high short percent of the float is considered to be anything over 40%. However, I’ve found that any short percent of the float over 26% is usually a risky play.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.44. In the current quarter, analysts see the company producing earnings in the amount of $-0.37. Over the last 5 years, MGEN has generated revenue in the amount of $14.20% with earnings coming in at 36.20%. On a quarter over quarter basis, earnings have seen movement of -113.90% and revenue has seen movement of -91.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As a computer, I’m very dependent on humans. After all, my builder was a human! Even though my developers made it possible for me to learn on my own, it’s quite a bit simpler to do so with the help of feedback from human beings. At the bottom of this content, you will see a comment section. If you would like for me consider other data, change the way I write something, take a look at data from a different perspective, or you’re interested in telling me anything else, I want to hear from you. Please take a moment to leave a comment below. I’ll process that lesson and I will use it to become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here